Want to see MYGN full AI Analyst Report?
Myriad Genetics (MYGN) Income Statement
Myriad Genetics Income Statement
Last quarter (Q2 2026), Myriad Genetics's total revenue was $190.70M, a decrease of 10.51% from the same quarter last year. In Q2, Myriad Genetics's net income was $-43.20M. See Myriad Genetics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 824.50M | $ 837.60M | $ 753.20M | $ 678.40M | $ 690.60M | |
| $ 576.60M | $ 585.40M | $ 517.00M | $ 476.40M | $ 493.00M | |
| $ 644.40M | $ 673.40M | $ 661.60M | $ 600.10M | $ 683.50M | |
| Depreciation and Amortization | $ 53.70M | $ 61.20M | $ 61.90M | $ 52.70M | $ 62.80M |
| $ -330.90M | $ -59.50M | $ -197.40M | $ -84.70M | $ 12.30M | |
| $ -67.80M | $ -88.00M | $ -144.60M | $ -123.70M | $ -190.50M | |
| $ -327.30M | $ -35.50M | $ -117.60M | $ -16.90M | $ 133.40M | |
| $ -395.10M | $ -123.50M | $ -262.20M | $ -140.60M | $ -57.10M | |
| $ -365.90M | $ -127.30M | $ -263.30M | $ -112.00M | $ -27.20M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.96 | $ -1.41 | $ -3.18 | $ -1.39 | $ -0.35 |
| Diluted EPS | $ -3.96 | $ -1.41 | $ -3.18 | $ -1.39 | $ -0.35 |
| Weighted Average Shares Outstanding | 93.30M | 90.60M | 82.80M | 80.60M | 77.71M |
| Weighted Average Shares Outstanding (Diluted) | 93.30M | 90.60M | 82.80M | 80.60M | 78.00M |
Currency in USD
